PSA水平与骨转移体积不一致与不良预后相关
本研究纳入2009至2025年多中心526例激素敏感性前列腺癌骨转移患者,评估骨扫描指数(BSI)与初始PSA比值(BSI/iPSA)的预后意义。生存树分析确定0.02为最佳截断值,高比值(≥0.02)与更短总生存期相关(HR 1.91,P<0.0001),倾向性评分匹配后仍显著(HR 1.63,P=0.0303),多因素分析显示其为总生存期的独立预后因素(HR 2.03,P=0.0046)。
要点
- BSI/iPSA比值≥0.02提示PSA水平与骨转移体积不一致,与更短总生存期独立相关。
- 高BSI/iPSA比值患者较少表现为仅PSA进展的复发模式(P=0.0122)。
- 该比值有助于识别非PSA产生型肿瘤,辅助个体化治疗决策。
核心结论
- PSA水平与骨转移体积不一致提示存在非PSA产生型肿瘤,与死亡风险增加相关。
研究设计与样本
- 多中心回顾性研究,纳入2009至2025年526例激素敏感性前列腺癌骨转移患者。
- 采用多因素Cox比例风险模型、Kaplan-Meier法、生存树分析和倾向性评分匹配。
主要发现
- 诊断时中位年龄75岁,初始PSA中位229.8 ng/mL,BSI中位1.6%。
- 生存树分析确定BSI/iPSA比值最佳截断值为0.02。
- 高BSI/iPSA比值(≥0.02)与更短总生存期相关(HR 1.91;P<0.0001)。
- 倾向性评分匹配后高比值仍与更短总生存期相关(HR 1.63;P=0.0303)。
- 多因素分析显示高BSI/iPSA比值为总生存期独立预后因素(HR 2.03;P=0.0046)。
关键数值与推荐
- BSI/iPSA比值≥0.02定义为高比值,<0.02为低比值。
临床怎么用
- 可将BSI/iPSA比值用于激素敏感性前列腺癌骨转移患者的预后分层。
- 高比值提示非PSA产生型肿瘤可能,支持个体化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the use of bone scan index (BSI)/initial prostate-specific antigen (iPSA) ratio, a novel biomarker that can reveal discordance between PSA level and bone metastasis volume, and to investigate its prognostic significance in patients with hormone-sensitive prostate cancer (PCa) and bone metastasis. PATIENTS AND METHODS: Clinical data were collected from 526 patients with bone metastatic PCa between 2009 and 2025 from multiple centres. Cancer-specific survival and overall survival (OS) were evaluated as clinical outcomes, and prognostic factors were analysed using multivariate Cox proportional hazard modelling and Kaplan-Meier methods. Survival tree analysis was performed to identify the optimal cut-off for stratifying prognosis. Propensity-score matching (PSM) was used to equalise patient baseline characteristics. RESULTS: The median age at diagnosis, initial PSA level and BSI were 75 years, 229.8 ng/mL and 1.6%, respectively. Survival tree analysis identified 0.02 as the optimal cut-off for BSI/iPSA ratio. Kaplan-Meier analysis showed that a high BSI/iPSA ratio (≥0.02) was associated with shorter OS compared with a low BSI/iPSA ratio (<0.02; hazard ratio [HR] 1.91; P < 0.0001). Statistical significance remained after PSM analysis (HR 1.63; P = 0.0303). Multivariate analysis showed that a high BSI/iPSA ratio was an independent prognostic factor for OS (HR 2.03; P = 0.0046). Notably, patients with a high BSI/iPSA ratio were less likely to have a PSA progression-only pattern of recurrence (P = 0.0122). CONCLUSIONS: Discordance between PSA level and bone metastatic volume indicated the presence of non-PSA-producing tumour and was correlated with increased risk of death. Our findings will help facilitate a personalised therapeutic approach for patients with metastatic prostate cancer.
引用
- Shirafuji T, Yamada Y, Sato K, et al. Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosis. BJU Int. 2025. PMID: 41231036. doi:10.1111/bju.70081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。